New guidance says start HIV treatment within 7 days of diagnosis – but is everyone ready?

Presentation by Brendan Maughan-Brown at IAS 2017. www.ias2017.org
Keith Alcorn
Published: 25 July 2017

Everyone diagnosed with HIV should be offered the option to start treatment within seven days of diagnosis and everyone who feels ready should have the option to start treatment on the day of diagnosis, the World Health Organization (WHO) has recommended.

The new guidance was issued on the opening day of the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris.

WHO's recommendation is based on the findings of a study conducted in Haiti, presented at the AIDS 2016 conference, which showed that people who started treatment on the day of HIV diagnosis were more likely to be retained in care and more likely to be virally suppressed a year later.

But, two studies presented on Monday at the conference highlight the need for better preparation of people who start treatment very quickly after diagnosis. The studies also highlight the need for research to identify better ways of screening for patients who are going to struggle with treatment, even if they accept an offer of a rapid start.

A study conducted in Uganda found that people who started treatment on the day of HIV diagnosis were two and half times more likely to become lost to clinic follow-up during the year after starting treatment than those who started treatment days or weeks after diagnosis.

However, the study also found that once people had been on treatment for at least a month their risk of being lost to follow-up began to fall sharply, and possession of a mobile phone also greatly reduced the risk of loss to follow-up.

A second study, carried out in Cape Town, found that readiness to start treatment immediately was associated with a better knowledge of antiretroviral therapy (ART) and knowing someone who had already experienced the positive health benefits of ART. People who were surprised by their diagnosis or who were otherwise healthy were around 55% less likely to consider themselves ready and motivated to start treatment. 

Uganda

The Ugandan study looked at risk factors for loss to follow-up in 600 people who started ART at Masaka’s Uganda Cares clinic between January 2012 and December 2014. The clinic began piloting 'test and start' in 2012. The study looked at correlates of loss to follow-up (failure to attend the clinic more than three months after the last scheduled appointment).

Just under two-thirds of the cohort were women (64.7%) and had a median CD4 cell count of 373 cells/mm3 at the time they started treatment. Fifteen per cent already had symptomatic HIV disease (WHO stage 3/4).

Fifty-five people were lost to care by December 2014, a cumulative incidence of 8.48% 12 months after starting treatment.

Loss to follow-up was associated with WHO stage 3 or 4 disease (aHR 3.78, 95% CI 1.70-8.41) and with suspected tuberculosis (aHR 3.42, 95% CI 1.19-9.81), but also with starting treatment on the day of diagnosis (aHR 2.49, 95% CI 1.07-5.78). Owning a mobile phone – and so being contactable by the clinic – protected against loss to follow-up (aHR 0.56, 95% CI 0.36-0.88).

Presenter Julius Kiwanuka of AIDS Healthcare Foundation Uganda said that when the data were reanalysed to check if starting a few days after diagnosis instead of on the same day made a difference, they still found that starting within a week of diagnosis was associated with a higher risk of loss to follow-up than deferred treatment.

"'Steep' ART initiation should be backed up by intensive pre-ART counselling," Julius Kiwanuka concluded. But is this necessary for everyone, and are there ways of distinguishing which patients might need more intensive support?

Readiness

'Test and start' policies have jettisoned pre-ART counselling requirements that were considered onerous and may have contributed to loss to follow-up before starting treatment. In some cases, guidelines required people to attend pre-ART preparation sessions for up to a month before starting treatment. But, what support do people need if they are to start treatment very quickly after diagnosis?

Previous research in southern Africa has found that 'treatment readiness' – the sense of being ready and motivated to start treatment – predicts whether or not people will start ART. It can be assessed by asking whether people think that ART will be beneficial, whether they feel motivated to start treatment, and whether they intend to start treatment soon.

The Cape Town study looked at factors associated with readiness in 87 people referred from a mobile health clinic to an ART clinic after HIV diagnosis. Approximately two-thirds were women and half were in good health with no HIV-related symptoms.

Face-to-face interviews probed readiness and barriers to care, asking four questions to assess readiness after participants had undergone pre-ART counselling:

  • 'Overall, how confident are you that antiretrovirals (ARVs) would have a positive effect on your health?'
  • 'How motivated are you to start ARVs?'
  • 'How likely is it that you’ll visit an HIV/ARV clinic in the next 30 days?'
  • 'How ready do you feel to start ARVs?'

Although most participants were ready to start ART on all measures, 28% reported some uncertainty regarding ART initiation.

Treatment readiness was lower among those surprised by their diagnosis (aOR:0.26,p < 0.05) and among healthier individuals (aOR:0.44,p < 0.01).

Readiness was greater among those who already had good knowledge about ART (aOR:4.31, p < 0.05) and among those who knew someone who had already experienced positive health effects of ART (aOR:2.65, p < 0.05). There were also strong trends that were not statistically significant owing to the small sample size, indicating that internalised stigma and a fear of side-effects were associated with lack of readiness, whereas an intention to disclose to a partner was associated with readiness for treatment.

Presenting the findings, Brendan Maughan-Brown of the Southern Africa Labour and Development Research Unit at the University of Cape Town said that the study results indicate the need for interventions at the time of ART referral that are tailored to better help individuals overcome their surprise at HIV diagnosis and come to terms with their HIV-positive status.

Preparing people for rapid treatment initiation also needs to overcome persisting suspicions about side-effects among people who are otherwise healthy, he added.

He said that the study findings couldn’t provide an instrument to differentiate patients according to readiness for treatment for use in everyday clinical practice, and that more research is needed on this subject.

A common thread in the findings of this study is the role that community awareness of ART, and of people doing well on treatment, is likely to have on people’s readiness to accept the idea of immediate treatment at diagnosis. Is individual treatment readiness a consequence of a community’s preparedness for HIV treatment, and will rapid ART initiation depend on the success of efforts to educate communities in advance of diagnosis about the benefits of antiretroviral treatment? 

References

Maughan-Browne B et al. Readiness for antiretroviral therapy: implications for linking HIV-infected individuals to care and treatment. 9th IAS Conference on HIV Science, Paris, abstract MOAD0101, July 2017.

View the abstract on the conference website.

Download the presentation slides from the conference website.

Kiwanuka J et al. Factors associated with loss to follow-up in a primary healthcare HIV clinic practising test and treat. 9th IAS Conference on HIV Science, Paris, abstract MOAD0102, July 2017.

View the abstract on the conference website.

Download the presentation slides from the conference website.

A webcast of this session is available on YouTube.

NAM's news coverage of the International AIDS Society's Conference on HIV Science has been made possible thanks to support from Gilead Sciences Europe Ltd. and Merck & Co. NAM's wider conference news reporting services have been supported by Janssen and ViiV Healthcare.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.